Jeil Pharmaceutical Receives Approval for SGLT-2 Class Diabetes Combination Drug 'Duglow'

Jeil Pharmaceutical announced on the 4th that it has obtained product approval from the Ministry of Food and Drug Safety for the diabetes combination drug ‘Duglow Tab’.

Jeil Pharmaceutical Headquarters View
[Photo by Jeil Pharmaceutical]

Duglow Tab is an improved new drug combining 'Dapagliflozin,' a sodium-glucose co-transporter (SGLT)-2 inhibitor, and 'Pioglitazone,' a thiazolidinedione (TZD) class agent.

The main ingredient, Dapagliflozin, lowers blood sugar by inhibiting glucose reabsorption in the kidneys, causing glucose to be excreted in the urine, while Pioglitazone improves insulin resistance to exert a blood sugar-lowering effect. Pioglitazone may cause side effects such as edema and weight gain. On the other hand, Dapagliflozin reduces fluid retention and decreases weight, offsetting the side effects of thiazolidinedione-class drugs. Therefore, Duglow Tab, which combines these two ingredients, is expected to provide not only the advantages of each component but also a complementary synergistic effect in their mechanisms of action when administered together.

Additionally, Duglow Tab is explained to reduce cardiovascular mortality and have effects on myocardial infarction, stroke, kidney disease, and blood pressure reduction. It carries a low risk of hypoglycemia and does not directly stimulate the pancreas, making it an effective and safe treatment option for patients with type 2 diabetes.

Jang Il-jun, head of the Diabetes and Antithrombotic Team at Jeil Pharmaceutical, stated, “Duglow Tab’s name combines ‘Duo’ from duo, ‘Gly’ from glycemic advantage indicating strong blood sugar reduction, and ‘low’ to signify lowering. According to the revised diabetes drug combination reimbursement criteria from April, it can be prescribed as a triple therapy with metformin for patients with type 2 diabetes, which is expected to greatly help improve diabetes patient treatment.”

This content was produced with the assistance of AI translation services.